Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: May 21, 2026
Breast cancer risk after ovarian cancer in patients with BRCA mutations: Implications in an era of improving survival.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 21, 2026
The Great Escape: the systems biology of endocrine resistance and lineage plasticity.
Journal: Endocrine-related cancer
Published: March 09, 2026
The Great Escape: Systems Biology of Endocrine Resistance and Lineage Plasticity.
Journal: Endocrine-related cancer
Published: March 09, 2026
HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer.
Journal: Cancer medicine
Published: January 02, 2025
Trends in breast cancer-specific death by clinical stage at diagnoses between 2000 and 2017.
Journal: Journal of the National Cancer Institute
Published: June 04, 2024
Navigating the Complexities of Brain Metastases Management.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 23, 2024
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer.
Journal: Breast cancer research and treatment
Published: February 28, 2024
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?
Journal: Future oncology (London, England)
Published: September 28, 2023
Intratumor spatial heterogeneity in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer.
Journal: Breast cancer research and treatment
Published: February 17, 2023
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Journal: The oncologist
Published: February 04, 2023
Last Updated: 09/26/2026